Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study

NCT03101514 is registered in ClinicalTrials.gov with First Affiliated Hospital of Harbin Medical University as lead sponsor.

NCT NCT03101514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03101514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2017
Completion date
February 1, 2021
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, radiotherapy